| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC66051 | WAY-333449 Featured |
|
|
| DC66052 | FGIN 1-43 Featured | FGIN 1-43 is an effective and specific ligand for the mitochondrial diazepam binding inhibitor (DBI) receptor (related to the production of neurosteroids). FGIN 1-43 enhances the transmission of GABA by inducing the production of neurosteroids, which can be used for research on anti-anxiety. |
|
| DC66053 | WAY-604663 Featured |
|
|
| DC66054 | WAY-639251 Featured |
|
|
| DC66055 | WYE-175761 Featured | CTP inhibitor; Inhibitor of the mitochondrial citrate transport protein; |
|
| DC66056 | Wnt/β-catenin agonist 4 Featured | Wnt/β-catenin agonist 4 (Derivative 83) is an agonist of Wnt that activates Wnt/β-catenin signal transmission. |
|
| DC66057 | 3,3'-(thiophen-2-ylmethylene)bis(2-methyl-1H-indole) Featured |
|
|
| DC66058 | 2-methoxy-5-(((3,4,5-trimethoxyphenyl)amino)methyl)phenyl (E)-but-2-enoate Featured |
|
|
| DC66059 | 2-(4-(Diethylamino)styryl)-1-methylpyridin-1-ium iodide Featured |
|
|
| DC66060 | TC HSD 21 Featured | TC HSD 21 is a potent 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitor with an IC50 of 14 nM. TC HSD 21 shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors. |
|
| DC66061 | WAY-301617 Featured | 11b-hydroxysteroid dehydrogenase type 1 inhibitor |
|
| DC66062 | 2-(3-fluorophenyl)-3-phenylimidazo[1,2-a]pyridine Featured |
|
|
| DC66063 | 1-([1,1'-biphenyl]-4-yl(4-fluorophenyl)methyl)-1H-imidazole Featured |
|
|
| DC66064 | WAY-656935 Featured | ROCK Inhibitor; inhibitor of ROCK, ERK, GSK, and AGC protein kinases; |
|
| DC66065 | WAY-339495 Featured | Antitumor histone acetyl transferase inhibitors; modulator of acetyltransferase/deacetylase activity; sirtuin modulators; sirtuin modulators; sirtuin modulators; sirtuin modulators; sirtuin modulators; |
|
| DC66066 | Transketolase-IN-4 Featured | Transketolase-IN-4 is a potent transketolase inhibitor (IC50=3.9 μM). Transketolase-IN-4 inhibits tumor cell proliferation of SW620, LS174T, and MIA PaCa-2. Transketolase-IN-4 is a possible Mycobacterium tuberculosis DXS inhibitor, with an IC50 value of 114.1 μM. |
|
| DC66067 | BMY 14802 Featured | BMY 14802 is a sigma-1 receptor (σ1R) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM. |
|
| DC66068 | WAY-326275 Featured | inhibitor of lethal toxin pathway; useful for modulating hepatocyte growth factor/scatter factor activity; |
|
| DC66069 | DAPK-IN-2 Featured | DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases. |
|
| DC66070 | WAY-620472 Featured | altering the lifespan of a eukaryotic organism; PPAR modulator; |
|
| DC66071 | 4-Hydroxyretinoic acid Featured | 4-Hydroxyretinoic acid (4-HRA) is a naturally occurring retinoid derivative with diverse biological effects. 4-Hydroxyretinoic acid is formed from retinol catalyzed by cytochrome P-450 isozyme(s), and is mainly metabolized by the liver in the body. 4-Hydroxyretinoic acid also serves as the substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. 4-Hydroxyretinoic acid regulates gene expression and cell differentiation via binding to nuclear receptor RAR (Retinoic Acid Receptor), and activates RARs and RXR-alpha, to induce cancer cell apoptosis. In addition, 4-Hydroxyretinoic acid is also involved in various physiological processes such as immune regulation, neuroprotection, and anti-oxidation. |
|
| DC66072 | TC-F2 Featured | TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders. |
|
| DC66073 | WAY-639497 Featured | altering the lifespan of a eukaryotic organism; antibacterial agent; |
|
| DC66074 | BTK ligand 1 Featured | BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosine kinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting Btk can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies. |
.gif)
|
| DC66075 | WAY-608306 Featured |
|
|
| DC66076 | SNX7 Featured | SNX7 is a Cyclin-Dependent Kinase Inhibitor (CDKI) pathway inhibitor. SNX7 can be used for research of senescence-related and other CDKI-related diseases. |
|
| DC66077 | DpC Featured | DpC is an anti-tumor agent. DpC inhibits cancer cell proliferation (IC50: 0.007-0.096 渭M). DpC synergizes with multiple anti-cancer therapeutics. |
|
| DC66078 | WAY-299026 Featured |
|
|
| DC66079 | NMDAR/TRPM4-IN-2 Featured | NMDAR/TRPM4-IN-2 (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. NMDAR/TRPM4-IN-2 shows neuroprotective activity. NMDAR/TRPM4-IN-2 prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC50 of 2.1 μM. NMDAR/TRPM4-IN-2 protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss. |
|
| DC66080 | (E)-1-methyl-4-(4-(methyl(2-(stearoyloxy)ethyl)amino)styryl)pyridin-1-ium Featured |
|
